Sulperazon-induced acute reactive thrombocytopenia during treatment of systemic lupus erythematosus: a case report.

Eur J Hosp Pharm

Department of Laboratory Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Published: July 2023

The purpose of this study is to report a patient who developed acute reactive thrombocytopenia while undergoing treatment with sulperazon for systemic lupus erythematosus (SLE). Sulperazon is a broad-spectrum antibiotic that can act against a wide range of microorganisms, but rarely causes severe thrombocytopenic events. We describe a 62-year-old man with new-onset acute reactive thrombocytopenia who experienced a precipitous fall in the platelet count from 168×10/L to 1×10/L within 29 hours after exposure to sulperazon. Sulperazon was immediately discontinued followed by administration of intravenous immunoglobulin for six consecutive days. The platelet count eventually recovered and petechiae at the injection sites improved. No complications secondary to acute reactive thrombocytopenia were observed except petechiae.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359788PMC
http://dx.doi.org/10.1136/ejhpharm-2021-002999DOI Listing

Publication Analysis

Top Keywords

acute reactive
16
reactive thrombocytopenia
16
systemic lupus
8
lupus erythematosus
8
platelet count
8
sulperazon-induced acute
4
reactive
4
thrombocytopenia
4
thrombocytopenia treatment
4
treatment systemic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!